XML 97 R78.htm IDEA: XBRL DOCUMENT v3.10.0.1
COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Mar. 06, 2018
May 17, 2017
Feb. 25, 2015
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Mar. 31, 2018
Mar. 31, 2017
Share-based Compensation       $ 439,328 $ 762,208 $ 1,034,740 $ 1,013,256 $ 1,540,580 $ 1,001,950
Purchase Commitment, Description On March 6, 2018, the Company signed a distribution agreement with Curexo Inc. for South Korea and as part of this agreement, the Company is obligated to buy a rehabilitative product from Curexo Inc. for $200,000 when this product is fully developed. It is not yet developed at September 30, 2018.                
Royalty on Sales,Percentage       1.00%   1.00%   1.00%  
Bionik Laboratories Corp. [Member]                  
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners   25.00%              
Third party [Member]                  
Description Of Contribution For Formation   Under the terms of the JV Contract, the JV Partner is required to contribute $290,000 within 30 days of formation, $435,000 12 months later and $725,000 60 months after the date of formation. The Company is required to contribute certain intellectual property to the China JV through a license.              
Noncontrolling Interest, Ownership Percentage by Parent   75.00%              
Exchangable Shares [Member]                  
Stock Issued During Period, Shares, Issued for Services     1,753            
Stock Transferred To Lenders     2,098            
Stock to be Reimbursed to Officers     2,134            
Share-based Compensation     $ 210,323            
Proceeds from (Repayments of) Debt     $ 241,185